Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

RT @tsuneyoshida: インフリキシマブの皮下注製剤(BS)の方が点滴より効果があったというmetwork meta analysis。 BS120mg/2w毎 vs IV3mg/kg/8w毎、とBSの方が圧倒的に投与量が多いだけかもしれないが、この用量で保険収載…

RT @tsuneyoshida: インフリキシマブの皮下注製剤(BS)の方が点滴より効果があったというmetwork meta analysis。 BS120mg/2w毎 vs IV3mg/kg/8w毎、とBSの方が圧倒的に投与量が多いだけかもしれないが、この用量で保険収載…

[hal-03240383] Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials by Bernard Combe et al. https://t.co/MhLOSs

RT @RheumNow: Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows…